BCAB vs CLYM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 09, 2026

BCAB

38.8
AI Score
VS
CLYM Wins

CLYM

50.9
AI Score

Investment Advisor Scores

BCAB

39score
Recommendation
SELL

CLYM

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BCAB CLYM Winner
Net Income -95.40M -27.22M CLYM
Operating Income -96.44M -30.57M CLYM
ROE -45.3% -11.4% CLYM
ROA -37.5% -11.1% CLYM
Total Assets 254.42M 246.29M BCAB
Cash 244.98M 44.11M BCAB
Current Ratio 12.48 31.45 CLYM

Relative Price Performance (Last 90 Days)

BCAB 1M: -48.7% · 3M: -55.9% CLYM 1M: -1.0% · 3M: +30.6%

Current Technical Phase

BCAB

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.5%), weak momentum, RSI 20

RSI (14): 20.2 · Price: $1.74

CLYM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.8 · Price: $14.25

Fundamentals Snapshot

Metric BCAB CLYM
Market Cap
Forward P/E -1.3 -14.2
Trailing P/E
Revenue (TTM)
Revenue Growth 0.3% 0.0%
Gross Margin -1.9%
Operating Margin 0.0% 0.0%
EPS -25.23 -0.82
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, CLYM is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.